<DOC>
	<DOCNO>NCT01451424</DOCNO>
	<brief_summary>To determine safety , pharmacokinetics efficacy 4 dos ( 3 , 6 , 12 , 24 mg ) Proellex premenopausal woman uterine fibroid confirm ultrasound . Drug administer vaginally .</brief_summary>
	<brief_title>Evaluation Safety , Pharmacokinetics , Efficacy Proellex Administered Vaginally Women With Uterine Fibroids</brief_title>
	<detailed_description>This study phase II , 5 arm study 12 week active dosing period . The study conduct 2 stage . In first stage , first 6 woman enrol treated 12mg dose level , addition require study assessment monitor 24-hour PK assessment Day 14 , daily trough assessment first 14 day . If , Visit 3 , Cmax AUC subject treat 12mg exceeds mean observed high safe oral dose administer ZP-204 study , subject enrol 12mg level discontinue , patient treat dose level , 6mg vaginal dose assess similar fashion . In second stage , remain subject randomize dose 3 , 6 , 12 24 mg. For subject 4-6 week placebo run-in period , establish baseline parameter ( bleed quality life ) follow treatment one three single-blind Proellex dose ( 3 , 6 12 mg daily , administer vaginally capsule form . ) The primary efficacy endpoint bleeding assess use Pictorial Blood Loss Assessment Chart ( PBAC ) 12 16 week treatment . The secondary endpoint change size uterine fibroid assess MRI improvement quality life assess use Uterine Fibroid Symptom Health-Related Quality Life questionnaire ( UFSQOL0 . Safety endpoint include significant adverse event , change physical examination result , and/or clinical laboratory result significantly outside normal range . For subject enrol Stage 2 , PK assess first last dos trough level every 2 week .</detailed_description>
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<criteria>Healthy adult female 18 47 year age uterine fibroid confirm ultrasound . Normal transvaginal ultrasound ( presence fibroid ) History menstrual event occur regular cycle Agreement attempt become pregnant Agreement limit alcohol consumption 2 drink per week avoid alcohol consumption within 48 hour visit Ability complete daily subject diary Willing discontinue hormonal contraceptive consent use double barrier contraceptive technique course study . Has negative pregnancy test Screening Baseline visit An exception pregnancy test requirement grant subject report surgical sterilization medical history A Body Mass Index ( BMI ) 18 39 inclusive Is available treatment followup visit . Subject postmenopausal woman , define either ; six ( 6 ) month ( immediately prior screen visit ) without menstrual period , prior hysterectomy and/or oophorectomy Subject pregnant lactating attempt expect become pregnant 6 month study period Women abnormally high liver enzymes liver disease . ( ALT AST exceed 1.5xULN AND total bilirubin exceed 1.5xULN screening confirm repeat ) . Received investigational drug 30 day prior screen study Women history PCOS Concurrent use testosterone , progestin , androgen , estrogen , anabolic steroid , DHEA hormonal product least 2 week prior screen study . Use oral contraceptive precede 2 week . Use DepoProveraÂ® precede 6 month . Has IUD place Women currently use narcotic Women currently take spironolactone Infectious disease screen positive HIV Hepatitis A , B C Clinically significant abnormal finding screen examination condition opinion investigator would interfere participant 's ability comply study instruction endanger participant take part study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>47 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>